Laboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Brazil.
Serviço Interdisciplinar de Neuromodulação (SIN), Departamento e Instituto de Psiquiatria, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, Brazil.
J Gerontol A Biol Sci Med Sci. 2022 Apr 1;77(4):851-860. doi: 10.1093/gerona/glab235.
BACKGROUND: Major depressive disorder (MDD) in older adults is a serious public health concern. Repetitive transcranial magnetic stimulation (rTMS) is a nonpharmacological intervention approved for MDD treatment in adults, but its value in older adults remains unknown. This study aims to systematically review and meta-analyze evidence of rTMS efficacy in MDD treatment among older adults. METHODS: We systematically reviewed the literature for randomized controlled trials (RCTs) and open-label studies assessing rTMS for the treatment of MDD in patients older than 50 years, published until June 2020. Random-effects meta-analyses using standardized mean differences (SMDs) were conducted to assess change in depression severity score (primary outcome), while odds ratios (ORs) were used to assess secondary categorical outcomes (response and remission). Additionally, univariate meta-regression analyses were performed to identify potential predictors of change in depression severity scores. RESULTS: Fourteen RCTs were included in meta-analyses and 26 studies (10 RCTs and 16 open-label studies) in meta-regression. Active rTMS was significantly superior to sham treatment for reduction of severity (SMD = 0.36; 95% CI = 0.13-0.60), as well as response (OR = 3.26; 95% CI = 2.11-5.04) and remission (OR = 4.63; 95% CI = 2.24-9.55). Studies were of moderate to high quality, with funnel plots and Egger's regression test not suggestive of publication bias. In meta-regressions, higher mean age and number of sessions were significantly associated with greater improvement. CONCLUSIONS: Our results support that rTMS is an effective, safe, and well-tolerated treatment for MDD in older adults and that it should be considered in the treatment of this vulnerable population.
背景:老年人的重度抑郁症(MDD)是一个严重的公共卫生问题。重复经颅磁刺激(rTMS)是一种非药物干预措施,已被批准用于成人 MDD 的治疗,但在老年人中的价值尚不清楚。本研究旨在系统地回顾和荟萃分析 rTMS 在治疗 50 岁以上老年人 MDD 中的疗效证据。
方法:我们系统地检索了截至 2020 年 6 月发表的评估 rTMS 治疗 50 岁以上患者 MDD 的随机对照试验(RCT)和开放标签研究的文献。使用标准化均数差(SMD)进行随机效应荟萃分析,以评估抑郁严重程度评分(主要结局)的变化,而使用比值比(OR)评估二级分类结局(反应和缓解)。此外,进行了单变量 meta 回归分析,以确定抑郁严重程度评分变化的潜在预测因素。
结果:共有 14 项 RCT 纳入荟萃分析,26 项研究(10 项 RCT 和 16 项开放标签研究)纳入荟萃回归分析。与假刺激相比,rTMS 治疗可显著降低严重程度(SMD = 0.36;95%CI = 0.13-0.60),以及反应(OR = 3.26;95%CI = 2.11-5.04)和缓解(OR = 4.63;95%CI = 2.24-9.55)。这些研究的质量为中等至较高,漏斗图和 Egger 回归检验均未提示存在发表偏倚。在荟萃回归中,较高的平均年龄和治疗次数与更大的改善显著相关。
结论:我们的结果支持 rTMS 是治疗老年人 MDD 的一种有效、安全且耐受性良好的治疗方法,应该考虑将其用于治疗这一脆弱人群。
J Gerontol A Biol Sci Med Sci. 2022-4-1
Ont Health Technol Assess Ser. 2016-3-1
Front Psychiatry. 2025-7-30
Front Psychiatry. 2024-8-8
J Neurol Neurosurg Psychiatry. 2024-10-16
Int Psychogeriatr. 2024-11